Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs 675

Quick answer

Neurology & CNS: NovaPharmaNews indexes 675 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Pipeline programs

Page 3 of 15

  1. KW-6500

    KYOWA KIRIN AUSTRALIA PTY LTD

    Parkinson's Disease

    phase 3 small molecule completed

    1 trial

  2. KY2025-328-02

    The First People's Hospital of Lianyungang

    Post-stroke Epilepsy

    phase 3 small molecule active

    1 trial

  3. Ketanest-S 25 Multi-dose for Non-psychotic therapy resistant…

    Disc Medicine

    Non-psychotic therapy resistant unipolar depression

    phase 3 small molecule active

    1 trial

  4. LB-102

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    4 trials

  5. LB-102 (50 mg tablet)

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  6. LECANEMAB

    Eisai Co.,

    Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid

    phase 3 small molecule active

    1 trial

  7. Laquinimod

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  8. Laquinimod

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    3 trials

  9. Laquinimod

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  10. Lecanemab

    Eisai Co.,

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial

  11. Levetiracetam

    UCB Pharma

    Epilepsy

    phase 3 small molecule completed

    1 trial

  12. Levetiracetam NORMON comprimidos recubiertos...

    The George Institute

    Down syndrome, Alzheimer's Disease

    phase 3 small molecule active

    1 trial

  13. Levodopa-Carbidopa Intestinal Gel (LCIG)

    AbbVie

    Advanced Parkinson's Disease

    phase 3 small molecule completed

    1 trial

  14. Lu AF35700

    H. Lundbeck A/S

    Treatment-resistant Schizophrenia

    phase 3 small molecule terminated

    1 trial

  15. Lurasidone

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar I Depression

    phase 3 small molecule completed

    1 trial

  16. MN39158

    Hoffmann-La Roche

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  17. MN39159

    Hoffmann-La Roche

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  18. MN45053

    Hoffmann-La Roche

    Neurological Disease

    phase 3 small molecule active

    1 trial

  19. MN45053

    Hoffmann-La Roche

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. MYL-1603N-3001

    Mylan Pharma UK

    Major Depression Disorder

    phase 3 small molecule active

    1 trial

  21. MYL-1603N-3002

    Mylan Pharma UK

    Major Depression Disorders

    phase 3 small molecule active

    1 trial

  22. Matched placebo for product, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 3 small molecule active

    1 trial

  23. N01269

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  24. NA_00090926

    United Therapeutics Europe Ltd

    TBI Depression

    phase 3 other completed

    1 trial

  25. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  26. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  27. NBI-1117568-SCZ3030

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  28. NBI-98854-ATS3019

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  29. NGAM-13

    Maze Therapeutics

    Pediatric acute-onset neuropsychiatric syndrome (PANS)

    phase 3 small molecule active

    1 trial

  30. NN6535-4725

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  31. NN6535-4730

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  32. NN6535-7519

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  33. NW-3509/023/III/2024

    Lacuna Pharma Pty Ltd

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  34. NXPLEVE/24/P3-6

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Refractory Partial Onset Epilepsy

    phase 3 small molecule active

    1 trial

  35. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 3 small molecule active

    1 trial

  36. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity in Participants With Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  37. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity With Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  38. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis (MS)

    phase 3 small molecule terminated

    1 trial

  39. Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis, Primary Progressive

    phase 3 small molecule active

    1 trial

  40. Ocrelizumab IV

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  41. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  42. Orelabrutinib

    Zenas BioPharma

    Multiple Sclerosis (MS) Primary Progressive

    phase 3 small molecule active

    1 trial

  43. Orelabrutinib

    Zenas BioPharma

    Secondary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  44. Oxcarbazepine XR

    SUPERNUS PHARMACEUTICALS, INC.

    Partial Epilepsy

    phase 3 small molecule completed

    1 trial

  45. PRAX-628-322

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  46. PROTO-BRAIN

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  47. Paliperidone palmitate

    Janssen Cilag International NV

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  48. Phase 1: Olanzapine

    Shanghai Mental Health Center

    Schizophrenia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

675 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.